To,
THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: MONOPHARMA

MAY 30, 2025

Sub: Outcome of Board Meeting

Dear Sir/Madam,

As per Regulation 30 and any other applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and in furtherance to our intimation letter date May 27TH, 2025 we hereby inform the stock exchange that the Board of Directors of the company at its meeting held today i.e. **FRIDAY MAY 30, 2025** inter-alia discussed and approved the following business item(s):

1. Received, considered and approved the annual audited standalone financial statements along with draft auditors' report for year ended March 31, 2025.
2. Received, considered and approved the annual audited consolidated financial statements along with draft auditors' report for year ended March 31, 2025.
3. Received, considered, approved and took note of audited standalone financial result for the year ended March 31, 2025.
4. Received, considered, approved and took note of audited consolidated financial result for the year ended March 31, 2025.
5. Any other agenda with the permission of the chair:
   A: Board took note of statement of deviation and variation from the proceeds of IPO for the year ended on March 31, 2025.

Kindly note that the meeting of the Board of Directors of the Company commenced at 4:00 p.m. and concluded at 8:30 p.m.

We request you to kindly take the same on your record.

Thanking You,

Yours Sincerely,

FOR, MONO PHARMACARE LIMITED

PANILAM LAKHATARIYA
Digitally signed by PANILAM LAKHATARIYA
Date: 2025.05.31 14:14:22 +05'30'

PANILAM LAKHATARIYA
MANAGING DIRECTOR
DIN: 07659275

Annexure A

DECLARATION

Under regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016,

It is hereby declared and confirmed that the Auditors' Report on Annual Audited Standalone financial results for the year ended on March 31, 2025 and Annual Audited Consolidated financial results for the year ended on March 31, 2025 of the company is with unmodified opinion.

We further declare that M/s KUMBHAT & CO LLP(FRN : 001609S), the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the audited Standalone and Consolidated financial results of the Company for the period ended on March 31,2025.

This declaration is issued in compliance of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2016.

Kindly take the same on your record.

FOR MONO PHARMACARE LIMITED

PANILAM LAKHATARIYA
MANAGING DIRECTOR
DIN: 07659275

Date: May 30, 2025
Place: AHMEDABAD

KUMBHAT & CO. LLP
Chartered Accountants

812, 8th Floor, Corporate Annexe,
Sonawala Road,
Goregaon (E), Mumbai-400063.
gaurang@kumbhatco.in
Ph.No.022-60600094

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Independent Auditors' Report on Audited Half Yearly Financial Results and year to date Results of the Mono Pharmacare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
MONO PHARMACARE LIMITED

Opinion

We have audited the accompanying half yearly Financial Results of **MONO PHARMACARE LIMITED** ("the Company") for the half year ended on March 31, 2025 and the year to date results for the period from April 01, 2024 to March 31, 2025, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these financial results as well as year to date results:

i. is presented in accordance with the requirements of Listing Regulations in this regard; and

ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and other Accounting principles generally accepted in India of the net profit and other financial information of the Company for the half year ended on March 31, 2025 and year to date results for the period from April 01, 2024 to March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are

relevant to our audit of the Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Financial Results

These half yearly financial results as well as year to date financial results have been prepared on the basis of the audited financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in the Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.

- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably

be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the half year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to Six months ended on September 30, 2024 which were subjected to a limited review by us, as required under the Listing Regulations.

For *KUMBHAT & CO.LLP*
Chartered Accountants
Firm Regn. No. 001609S/S000162

Gaurang Champaklal Unadkat

Digitally signed by Gaurang Champaklal Unadkat
Date: 2025.05.30 23:37:06 +05'30'

Gaurang C. Unadkat
Partner
Mem.No. 131708
UDIN: **25131708BMIDXU3517**

Place: Mumbai
Dated: May 30th, 2025

MONO PHARMACARE LIMITED

Registered Office: 1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007
CIN:U24304GJ2022PLC136193
Website:www.monopharmacareltd.com
Email: info@monopharmacareltd.com

Statement of Audited Standalone Financial Results for the Half Year and year ended on March 31,2025

(Rs. in Lakhs)

	Particulars	For the Half Year Ended			Year Ended	
		March 31, 2025	September 30, 2024	March 31, 2024	March 31, 2025	March 31, 2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from operation	3825.77	4438.32	3612.12	8264.08	7071.99
II	Other income	175.18	78.39	91.81	253.57	169.66
III	**Total Revenue (I + II)**	**4000.94**	**4516.71**	**3703.93**	**8517.65**	**7241.65**
IV	**Expenses**					
	Purchase of Traded Goods	3783.00	4326.19	3474.93	8109.19	7021.58
	(Increase)/Decrease in Stock	-303.59	-376.13	-130.47	-679.72	-581.19
	Employee Benefits Expenses	147.56	118.74	138.89	266.30	244.53
	Finance Cost	64.92	59.34	63.67	124.27	121.31
	Depreciation and Amortisation Cost	5.18	3.17	4.12	8.36	7.87
	Other expenses	207.06	104.88	87.21	311.94	141.89
	Total Expenses	**3904.13**	**4236.19**	**3638.35**	**8140.33**	**6955.99**
V	**Profit before tax Extraordinary and Exceptional Items (III - IV)**	**96.81**	**280.51**	**65.59**	**377.32**	**285.66**
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	**Extraordinary Items And Tax (V- VI)**					
	Prior Period Expenses	0.00	0.00	0	0.00	0.00
VIII	**Profit Before Tax**	**96.81**	**280.51**	**65.59**	**377.32**	**285.66**
IX	Tax Expenses					
	(1) Current Tax	19.60	52.00	-0.80	71.60	37.50
	(2) Deferred Tax	-2.52	-0.78	8.69	-3.30	3.92
X	**Profit (Loss) for the Period**	**79.73**	**229.29**	**57.70**	**309.02**	**244.24**
XI	Earning per Equity share :					
	(1) Basic	0.45	1.30	0.38	1.75	1.59
	(2) Diluted	0.45	1.30	0.38	1.75	1.59

Notes:

1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on 30th May,2025 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2.The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3.Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable.Secondary segmental reporting on the basis of the geographical location of the customers is as below :

(Rupees in lakhs)

Sr.No	Particulars	Half year ended on			Year ended on	
		March 31,2025 Audited	September 30,2024 Unaudited	March 31,2024 Audited	March 31,2025 Audited	March 31,2024 Audited
1	India	3825.77	4438.32	3612.12	8264.08	7071.99
2	South Asian Countries	-	-	-	-	-
3	Rest of the World	-	-	-	-	-
	Total	3825.77	4438.32	3612.12	8264.08	7071.99

4.The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2025, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The company came with an Initial Public Offer of equity shares on 28th Aug., 2023 and closed on August 30,2023. The initial public offer ("IPO") was for 53,00,000 equity shares of face value of Rs. 10 each at premium of Rs. 18 per share aggregating to INR 1484.00 lakhs. The shares of the company were listed on the National Stock Exchange of India Limited, Emerge Platform on September 7, 2023

6. The details of utilization of IPO Proceeds are as per the table set forth below:

S. No.	Particulars	Planned as per Prospectus (Rs. In Lakhs)	Utilised till 31st March,2025 (Rs. In Lakhs)	Pending to be Utilised (Rs. In Lakhs)
1	Working Capital Requirements	898.00	898.00	-
2	General Corporate Purpose	366.00	366.00	-
3	Issue expenses	220.00	220.00	-
	Total Proceeds from the Issue	**1,484.00**	**1,484.00**	**-**

7. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

8.Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Pankaj G. Lakhotariya
Chairman & Managing Director
DIN: 07659275

Date: May 30,2025
Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office: 1A Krishkal Apartment Opp Mahalaxmi Temple Paldi Ahmedabad Gujarat Pin 380007
CIN:U24230GJ2022PLC136193
Website: www.monopharmacare.com
Email: info@monopharmacare.com

Standalone Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars	As at March 31st, 2025	As at 31st March, 2024
I.	**EQUITY AND LIABILITIES**		
(1)	**Shareholders' Funds**		
	(a) Share Capital	1766.86	1766.86
	(b) Reserve and surplus	1353.06	1044.04
		3119.92	**2810.90**
(2)	**Non-current liabilities**		
	(a) Long -term borrowings	1354.56	433.53
	(b) Long -term Provisions	8.38	4.29
		1362.94	**437.82**
(3)	**Current Liabilities**		
	(a) Short Term Borrowings	1014.72	893.46
	(b) Trade Payables	932.29	291.73
	(c) Other Current Liabilities	88.71	79.47
	(d) Short- term Provisions	88.23	26.95
		2123.95	**1291.61**
	TOTAL EQUITY AND LIABILITES	**6606.81**	**4540.32**
II.	**ASSETS**		
(1)	**Non Current Assets**		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	21.32	12.95
	(ii) Intangible Assets	1.00	1.34
	(iii) WIP	1.80	
	(b) Non-Current Investments	1083.94	359.49
	(c) Deferred tax assets (Net)	4.47	1.17
	(d) Long-term loans and advances	0.75	1.45
		1113.27	**376.40**
(2)	**Current Assets**		
	(a) Inventories	2779.03	2099.31
	(b) Trade Receivables	1889.70	1744.21
	(c) Cash and Cash Equivalents	11.11	25.05
	(d) Short Term Loans and Advances	768.39	227.62
	(e) Other Current Assets	45.30	67.72
		5493.54	**4163.92**
	TOTAL ASSETS	**6606.81**	**4540.32**

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Date: May 30,2025
Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office:1A,Krinkal Apartment,Opp Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007
CIN:U24304GJ2022PLC136193
Website:www.monopharmacareltd.com
Email: info@monopharmacareltd.com

Cash Flow statement for the year ended on March 31,2025

(Rs. in Lakhs)

Particulars	March 31, 2025	March 31, 2024
Cash flow from operating activities		
Profit/(loss) before tax	494.39	285.66
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	8.36	7.87
Finance Cost	124.27	121.31
Operating profit/(loss) before working capital changes	**627.02**	**414.83**
Movements in working capital:		
Increase/(decrease) in trade payables	640.57	82.40
Increase/(decrease) in other current liabilities	9.24	17.53
Increase/(decrease) in short term provision	90.77	-17.90
Increase/(decrease) in short term borrowings	121.26	-13.59
Decrease/(increase) in Inventories	-796.79	-581.19
Decrease/(increase) in trade receivables	-145.49	-935.82
Decrease/(increase) in short-term loans and advances	-540.77	81.04
Decrease/(increase) in other Current Assets	22.42	-41.45
Cash generated from Operations	**28.24**	**-994.14**
Less: Direct taxes paid	101.10	-37.50
Net Cash from Operating Activities (A)	**129.34**	**-1031.64**
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-18.18	-3.00
Purchase of Investment	-724.45	-162.94
Net cash flow from/(used in) investing activities (B)	**-742.63**	**-165.94**
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	921.03	90.05
Payment / (Repayment) of Long term Loan advance	0.70	0.00
Long term Provision	4.09	4.29
Proceeds from issue of equity shares	0.00	530.00
Securities Premium on Allotment of Equity Shares	0.00	954.00
Utilised for IPO Expenses	**0.00**	**-257.26**
Finance Cost	-124.27	-121.31
Net cash flow from/(used in) financing activities (C)	**801.55**	**1199.78**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	188.26	2.19
Cash and cash equivalents at the beginning of the year	25.05	22.86
Cash and cash equivalents at the end of the year	11.11	25.05
Net increase/(decrease) in cash and cash equivalents	**-13.94**	**-2.19**

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Date: May 30,2025
Place: Ahmedabad

KUMBHAT & CO. LLP
Chartered Accountants

812, 8th floor, Corporate Annexe
Sonawala Road,
Goregaon (E), Mumbai-400063.
Mumbai@kumbhatco.in
Ph.No.022-60600094

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

Independent Auditors' Report on Consolidated Audited Half Yearly Financial Results and year to date Results of the Mono Pharmacare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Mono Pharmacare Limited

Opinion

We have audited the accompanying consolidated half yearly Financial Results of **MONO PHARMACARE LIMITED** ("the Company") and it's Two subsidiary companies for the half year ended on March 31, 2025 and the year to date results for the period from April 01, 2024 to March 31, 2025, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the our audit report on separate financial statement of the subsidiary Company referred to in Other Matters section below, these consolidated financial results as well as year to date results:

i. is presented in accordance with the requirements of Listing Regulations in this regard; and

ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards and other Accounting principles generally accepted in India of the net profit and other financial information of the Company for the half year ended on March 31, 2025 and year as well as year to date results for the period from April 01, 2024 to March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of the Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

These half yearly financial results as well as year to date financial results have been prepared on the basis of the audited financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in the Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from

fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.

- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Accompanying statements includes the audited financial statement and other financial information, in respect of Two subsidiaries, whose financial statement includes total assets of Rs. 5250.72 lakhs as at March 31, 2025 and total revenues of Rs.10046.62 lakhs for the year ended March 31, 2025, total net profit after tax of Rs.157.26 lakhs for the year ended March 31, 2025 as considered in the Statement which have been audited by their respective independent auditors.

Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the report of the above auditor. The Statement includes the results for the half year ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to Six months ended on September 30, 2024 which were subjected to a limited review by us, as required under the Listing Regulations.

For KUMBHAT & CO. LLP
Chartered Accountants
Firm Regn. No. 001609S/S000162

Gaurang Champaklal Unadkat
Digitally signed by Gaurang Champaklal Unadkat
Date: 2025.05.30 23:37:48 +05'30'

Gaurang C. Unadkat
Partner
Mem.No. 131708
UDIN: **25131708BMIDXV7726**

Place: Mumbai
Dated: May 30th, 2025

MONO PHARMACARE LIMITED

Registered Office: 1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007
CIN:U24304GJ2022PLC136193
Website:www.monopharmacareltd.com
Email: infomonopharmacareltd.com

Statement of Audited Consolidated Financial Results for the half Year and year ended on March 31, 2025

(Rs. in Lakhs)

	Particulars	For the Half Year Ended			Year Ended	
		March 31, 2025	September 30, 2024	March 31, 2024	March 31, 2025	March 31, 2024
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from operation	8118.22	8716.28	5580.90	16834.49	12234.02
II	Other income	93.61	4.27	6.04	97.88	9.54
III	**Total Revenue (I + II)**	**8211.83**	**8720.55**	**5586.94**	**16932.38**	**12243.56**
IV	**Expenses**					
	Purchase of Traded Goods	8060.31	8480.82	5415.91	16541.13	12028.25
	(Increase)/Decrease in Stock	-764.30	-545.06	-378.35	-1309.35	-960.65
	Employee Benefits Expenses	208.47	170.21	170.10	378.67	351.39
	Finance Cost	246.25	156.31	158.63	402.55	308.29
	Depreciation and Amortisation Cost	6.44	6.42	6.42	12.87	11.52
	Other expenses	323.58	136.64	127.47	460.22	182.15
	Total Expenses	**8080.75**	**8405.34**	**5500.18**	**16486.08**	**11920.95**
V	**Profit before tax Extraordinary and Exceptional Items (III - IV)**	**131.08**	**315.21**	**86.76**	**446.29**	**322.60**
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII	**Extraordinary Items And Tax (V- VI)**					
	Prior Period Expenses	0.00	0.00	0	0.00	0.00
VIII	**Profit Before Tax**	**131.08**	**315.21**	**86.76**	**446.29**	**322.60**
IX	Tax Expenses					
	(1) Current Tax	53.05	85.95	19.50	139.00	72.80
	(2) Deferred Tax	-4.08	0.78	8.69	-3.30	3.92
X	**Profit (Loss) for the Period**	**73.96**	**230.04**	**58.57**	**310.59**	**245.88**
XI	**Minority Interest**	**-0.82**	**-0.75**	**-0.88**	**-1.57**	**-0.75**
XII	**Profit/(Loss) for the year after Taxes and Minority Interest**	**73.13**	**229.29**	**57.70**	**309.02**	**229.29**
XIII	Earning per Equity share :					
	(1) Basic	0.45	1.30	0.38	1.75	1.58
	(2) Diluted	0.45	1.30	0.38	1.75	1.58

Notes:

1.The above results were reviewed and recommended by the Audit Committee, at its meeting held on 30th May,2025 for approval by the Board and these results were approved and taken on record at the meeting of the Board of Directors of the Company held on that date. The Statutory Auditors have expressed an unqualified opinion.

2.The Company is listed on the SME platform of the National Stock Exchange of India Limited and the provisions of the IND AS as per rule 4 of the Companies (Indian Accounting Standards) Rules, 2015, Reconciliation of Profit and Loss and Reconciliation of Equity does not apply to the company and hence not reported.

3.Segment Reporting : The company is in the business of distribution of pharmaceutical items. Therefore disclosures under Accounting Standard 17- Primary Segment Reporting is not applicable.Secondary segmental reporting on the basis of the geographical location of the customers is as below :

(Rupees in lakhs)

Sr.No	Particulars	Half year ended on			Year ended on	
		March 31,2025 Audited	September 30,2024 Unaudited	March 31,2024 Audited	March 31,2025 Audited	March 31,2024 Audited
1	India	8118.22	8716.28	5580.90	16834.49	12234.02
2	South Asian Countries	-	-	-	-	-
3	Rest of the World	-		-	-	-
	Total	8118.22	8716.28	5580.90	16834.49	12234.02

4.The information presented above is extracted from the Audited Standalone Financial Statements for the financial year ended 31st March, 2025, and are prepared in accordance with the Accounting Standards as issued by the Institute of Chartered Accountants of India and as specified in Section 133 of the Companies Act, 2013 and the relevant rules thereof.

5. The company came with an Initial Public Offer of equity shares on 28th Aug., 2023 and closed on August 30,2023. The initial public offer ("IPO") was for 53,00,000 equity shares of face value of Rs. 10 each at premium of Rs. 18 per share aggregating to INR 1484.00 lakhs. The shares of the company were listed on the National Stock Exchange of India Limited, Emerge Platform on September 7, 2023

6. The details of utilization of IPO Proceeds are as per the table set forth below:

S. No.	Particulars	Planned as per Prospectus (Rs. In Lakhs)	Utilised till 31st March,2025 (Rs. In Lakhs)	Pending to be Utilised (Rs. In Lakhs)
1	Working Capital Requirements	898.00	898.00	-
2	General Corporate Purpose	366.00	366.00	-
3	Issue expenses	220.00	220.00	-
	Total Proceeds from the Issue	**1,484.00**	**1,484.00**	-

7. The above financial results are available on the website of the company i.e. www.monopharmacareltd.com and on the website of emerge platform of National Stock Exchange i.e. www.nseindia.com

8.Figures for previous half year/ year have been regrouped wherever necessary.

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Pankaj B. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Date: May 30,2025
Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office:1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007

CIN:U24304GJ2022PLC136193

Website:www.monopharmacareltd.com

Email: info@monopharmacareltd.com

Consolidated Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars	As at March 31st, 2025	As at 31st March, 2024
I.	**EQUITY AND LIABILITIES**		
(1)	**Shareholders' Funds**		
	(a) Share Capital	1766.86	1768.80
	(b) Reserve and surplus	1353.06	1042.10
	Minority Interest	3.52	1.94
		3123.43	**2812.84**
(2)	**Non-current liabilities**		
	(a) Long -term borrowings	2596.14	1712.49
	(b) Long -term Provisions	8.38	4.29
		2604.52	**1716.78**
(3)	**Current Liabilities**		
	(a) Short Term Borrowings	2759.88	2431.55
	(b) Trade Payables	1879.83	968.51
	(c) Other Current Liabilities	482.20	119.35
	(d) Short- term Provisions	155.62	62.25
		5277.55	**3581.66**
	TOTAL EQUITY AND LIABILITES	**11005.50**	**8111.27**
II.	**ASSETS**		
(1)	**Non Current Assets**		
	(a) Property, Plants & Equipment		
	(i) Tangible Assets	98.21	89.90
	(ii) Intangible Assets	1.00	1.34
	(iii) WIP	1.80	0.00
	(b) Non-Current Investments	0.00	0.00
	(c) Deferred tax assets (Net)	4.47	1.17
	(d) Long-term loans and advances	1.30	2.50
		106.77	**94.91**
(2)	**Current Assets**		
	(a) Inventories	5538.61	4229.26
	(b) Trade Receivables	4188.75	3159.03
	(c) Cash and Cash Equivalents	69.76	36.27
	(d) Short Term Loans and Advances	1013.92	471.49
	(e) Other Current Assets	87.68	120.32
		10898.73	**8016.36**
	TOTAL ASSETS	**11005.50**	**8111.27**

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Date: May 30,2025
Place: Ahmedabad

MONO PHARMACARE LIMITED

Registered Office:1A,Krinkal Apartment,Opp.Mahalaxmi Temple,Paldi,Ahmedabad,Gujarat,Pin-380007
CIN:U24304GJ2022PLC136193
Website:www.monopharmacareltd.com
Email: info@monopharmacareltd.com

Cash Flow statement for the year ended on March 31,2025

(Rs. in Lakhs)

Particulars	March 31, 2025	March 31, 2024
Cash flow from operating activities		
Profit/(loss) before tax	446.29	322.60
Non-cash adjustments to reconcile profit before tax to net cash flows		
Depreciation	12.87	11.52
Finance Cost	402.55	308.29
Operating profit/(loss) before working capital changes	**861.71**	**642.42**
Movements in working capital:		
Increase/(decrease) in trade payables	911.32	292.56
Increase/(decrease) in other current liabilities	362.86	1.34
Increase/(decrease) in short term provision	93.37	-13.60
Increase/(decrease) in short term borrowings	328.34	182.81
Decrease/(increase) in Inventories	-1309.35	-960.64
Decrease/(increase) in trade receivables	-1029.72	-971.96
Decrease/(increase) in short-term loans and advances	-542.43	63.88
Decrease/(increase) in other Current Assets	32.63	-41.00
Cash generated from Operations	**-291.27**	**-804.18**
Less: Direct taxes paid	-139.00	-73.00
Net Cash from Operating Activities (A)	**-430.27**	**-877.18**
Cash flows from investing activities		
Sale/(Purchase) of Fixed Assets	-22.63	-17.51
Purchase of Investment	0.00	57.34
Net cash flow from/(used in) investing activities (B)	**-22.63**	**39.84**
Cash flow from financing activities		
Acceptance / (Repayment) of Long Term Loan	883.66	-88.55
Payment / (Repayment) of Long term Loan advance	1.20	0.00
Long term Provision	4.09	0.00
Proceeds from issue of equity shares	0.00	696.74
Securities Premium on Allotment of Equity Shares	0.00	531.94
Finance Cost	-402.55	-308.29
Net cash flow from/(used in) financing activities (C)	**486.39**	**831.84**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	33.49	-5.50
Cash and cash equivalents at the beginning of the year	36.27	41.77
Cash and cash equivalents at the end of the year	69.76	36.27
Net increase/(decrease) in cash and cash equivalents	**33.49**	**-5.50**

For and on behalf of the Board of Directors
Mono Pharmacare Limited

Panilam S. Lakhatariya
Chairman & Managing Director
DIN: 07659275

Date: May 30,2025
Place: Ahmedabad

KUMBHAT & CO LLP
Chartered Accountants

812, 8th Floor, Corporate Annexe,
Sonawala Road,
Goregoan (E), Mumbai-400063.
gaurang@kumbhatco.in

Ph.No.022-60600094

Offices at CHENNAI- COIMBATORE - MUMBAI –BANGALORE

STATEMENT OF FUNDS UTILIZED

Pursuant to Regulation 32(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as **'listing regulations'**), given below is the statement of utilization of funds of M/s. **Mono Pharmacare Limited** having their office at 1A, Krinkal Apartment Opp. Mahalaxmi Temple, Paldi Ahmedabad-Gujarat 380007 for the period ended on March 31, 2025.

Object of the IPO proceeds from the initial public offer (IPO) as disclosed in the Company's prospectus dated August 22, 2023			
			(Amount in lakhs)
Objects as stated in the prospectus	**Projected Utilization of proceeds as per prospectus**	**Actual Utilization of proceeds upto 31-03-2025**	**Pending for Utilization of proceeds upto 31-03-2025**
Working Capital requirements	898.00	898.00	-
General Corporate Purpose	366.00	366.00	-
Issue Expenses	220.00	220.00	-
Total	**1484.00**	**1484.00**	**-**

We have verified the above details from the Initial Public Offer documents dated August 22, 2023 and books of accounts and other relevant records furnished to us by the Company.

For, **KUMBHAT & CO LLP**
Chartered Accountants
Firm Regn. No. S000162/001609S

Gaurang Champaklal Unadkat
Digitally signed by Gaurang Champaklal Unadkat
Date: 2025.05.30 23:28:53 +05'30'

CA Gaurang Unadkat
Partner
Mem. No. 131708
UDIN: **25131708BMIDXW6705**
Place: Mumbai
Date: May 30, 2025